P30GM145500

STEM Cells and Aging - Overall Abstract

The long-term goal of the Center of Biomedical Research Excellence (COBRE) for Stem Cells and Aging is to develop a multidisciplinary translational center for stem cells and aging biology and therapeutics. This center aims to focus on the underlying mechanisms and therapeutic potentials in the stem cell and aging fields. These two areas of endeavor overlap extensively, with one holding the promise of tissue restoration in a wide variety of disorders, while the other underlies diseases that impact everyone and lead to death.

Since the start of the COBRE nine years ago, 17 junior investigators have received either full projects or pilots. Additionally, they have published 369 research articles and accumulated extramural funding of over $20,000,000, largely from NIH. Currently, seven of these individuals are still funded, while 13 have sustained or advanced in their academic fields, with three entering the biotechnology field. Furthermore, since their COBRE funding, five have received promotions at Brown University.

The main objective of the Phase 3 COBRE is to strengthen and transition the COBRE research infrastructure into a competitive, independent, and self-sustaining academic center of excellence - the Center for Stem Cells and Aging Biology and Therapeutics in five years. To achieve this main objective, four specific aims are proposed as follows:

1) To provide strong leadership, structure, and support to enhance translational stem cell and aging research. This will be accomplished by providing critical equipment and unique expertise in flow cytometry, viral construction, and extracellular isolation and characterization.

2) To facilitate and develop the flow cytometry, lentivirus construct, and the extracellular vesicle cores. This will be achieved by evaluating and focusing the performance of the cores toward the goal of long-term independence, sustainability, and regional growth.

3) To guide the pilot project program in translational stem cell and aging-related research toward extramural funding. This will be done through expert mentorship from successful local faculty, supported by the administrative core.

4) To enhance translational research in the Rhode Island community by encouraging and enabling collaborations between clinicians and basic researchers at the junior and senior investigator levels.

Our vision is that by sustaining and transitioning the established high-caliber research infrastructure, we will enable clinicians to work side-by-side with basic research scientists, junior investigators, and senior investigators. This collaborative effort will lead to the development of insights into diseases and disorders of stem cells and aging, ultimately resulting in effective clinical therapeutic approaches.

Rhode Island Hospital

THE NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES (NIGMS) SUPPORTS BASIC RESEARCH THAT INCREASES OUR UNDERSTANDING OF BIOLOGICAL PROCESSES AND LAYS THE FOUNDATION FOR ADVANCES IN DISEASE DIAGNOSIS, TREATMENT, AND PREVENTION. NIGMS ALSO SUPPORTS RESEARCH IN SPECIFIC CLINICAL AREAS THAT AFFECT MULTIPLE ORGAN SYSTEMS: ANESTHESIOLOGY AND PERI-OPERATIVE PAIN, CLINICAL PHARMACOLOGY ?COMMON TO MULTIPLE DRUGS AND TREATMENTS, AND INJURY, CRITICAL ILLNESS, SEPSIS, AND WOUND HEALING.? NIGMS-FUNDED SCIENTISTS INVESTIGATE HOW LIVING SYSTEMS WORK AT A RANGE OF LEVELSFROM MOLECULES AND CELLS TO TISSUES AND ORGANSIN RESEARCH ORGANISMS, HUMANS, AND POPULATIONS. ADDITIONALLY, TO ENSURE THE VITALITY AND CONTINUED PRODUCTIVITY OF THE RESEARCH ENTERPRISE, NIGMS PROVIDES LEADERSHIP IN SUPPORTING THE TRAINING OF THE NEXT GENERATION OF SCIENTISTS, ENHANCING THE DIVERSITY OF THE SCIENTIFIC WORKFORCE, AND DEVELOPING RESEARCH CAPACITY THROUGHOUT THE COUNTRY.

93.859 - Biomedical Research and Research Training

National Institute of General Medical Sciences (NIGMS) [HHS - NIH]

Providence, Rhode Island 029034923 United States

Single Zip Code

Limited Competition: Centers of Biomedical Research Excellence (COBRE) Phase III - Transitional Centers (P30 Clinical Trial Optional) (PAR-20-115)

Amendment Since initial award the total obligations have increased 193% from $1,240,745 to $3,634,135.